Literature DB >> 20106965

The large hydrophilic loop of presenilin 1 is important for regulating gamma-secretase complex assembly and dictating the amyloid beta peptide (Abeta) Profile without affecting Notch processing.

Johanna Wanngren1, Jenny Frånberg, Annelie I Svensson, Hanna Laudon, Fredrik Olsson, Bengt Winblad, Frank Liu, Jan Näslund, Johan Lundkvist, Helena Karlström.   

Abstract

Gamma-secretase is an enzyme complex that mediates both Notch signaling and beta-amyloid precursor protein (APP) processing, resulting in the generation of Notch intracellular domain, APP intracellular domain, and the amyloid beta peptide (Abeta), the latter playing a central role in Alzheimer disease (AD). By a hitherto undefined mechanism, the activity of gamma-secretase gives rise to Abeta peptides of different lengths, where Abeta42 is considered to play a particular role in AD. In this study we have examined the role of the large hydrophilic loop (amino acids 320-374, encoded by exon 10) of presenilin 1 (PS1), the catalytic subunit of gamma-secretase, for gamma-secretase complex formation and activity on Notch and APP processing. Deletion of exon 10 resulted in impaired PS1 endoproteolysis, gamma-secretase complex formation, and had a differential effect on Abeta-peptide production. Although the production of Abeta38, Abeta39, and Abeta40 was severely impaired, the effect on Abeta42 was affected to a lesser extent, implying that the production of the AD-related Abeta42 peptide is separate from the production of the Abeta38, Abeta39, and Abeta40 peptides. Interestingly, formation of the intracellular domains of both APP and Notch was intact, implying a differential cleavage activity between the epsilon/S3 and gamma sites. The most C-terminal amino acids of the hydrophilic loop were important for regulating APP processing. In summary, the large hydrophilic loop of PS1 appears to differentially regulate the relative production of different Abeta peptides without affecting Notch processing, two parameters of significance when considering gamma-secretase as a target for pharmaceutical intervention in AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20106965      PMCID: PMC2838274          DOI: 10.1074/jbc.M109.055590

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Partial purification and characterization of gamma-secretase from post-mortem human brain.

Authors:  Mark R Farmery; Lars O Tjernberg; Sharon E Pursglove; Anna Bergman; Bengt Winblad; Jan Näslund
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

2.  Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

Authors:  Lynn A Hyde; Nansie A McHugh; Joseph Chen; Qi Zhang; Denise Manfra; Amin A Nomeir; Hubert Josien; Thomas Bara; John W Clader; Lili Zhang; Eric M Parker; Guy A Higgins
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

3.  Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Authors:  Samir Kumar-Singh; Jessie Theuns; Bianca Van Broeck; Daniel Pirici; Krist'l Vennekens; Ellen Corsmit; Marc Cruts; Bart Dermaut; Rong Wang; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

4.  gamma-Secretase complexes containing N- and C-terminal fragments of different presenilin origin retain normal gamma-secretase activity.

Authors:  Kia Strömberg; Emil M Hansson; Hanna Laudon; Susanne Bergstedt; Jan Näslund; Johan Lundkvist; Urban Lendahl
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

5.  Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase.

Authors:  Nobuto Kakuda; Satoru Funamoto; Sousuke Yagishita; Mako Takami; Satoko Osawa; Naoshi Dohmae; Yasuo Ihara
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

6.  Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.

Authors:  Mostafa Bentahir; Omar Nyabi; Jan Verhamme; Alexandra Tolia; Katrien Horré; Jens Wiltfang; Hermann Esselmann; Bart De Strooper
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

7.  A nine-transmembrane domain topology for presenilin 1.

Authors:  Hanna Laudon; Emil M Hansson; Karin Melén; Anna Bergman; Mark R Farmery; Bengt Winblad; Urban Lendahl; Gunnar von Heijne; Jan Näslund
Journal:  J Biol Chem       Date:  2005-07-25       Impact factor: 5.157

Review 8.  A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: are we progressing toward therapy?

Authors:  Katleen Dillen; Wim Annaert
Journal:  Int Rev Cytol       Date:  2006

Review 9.  When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease.

Authors:  Michael S Wolfe
Journal:  EMBO Rep       Date:  2007-02       Impact factor: 8.807

10.  Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway.

Authors:  Dragana Spasic; Alexandra Tolia; Katleen Dillen; Veerle Baert; Bart De Strooper; Stefan Vrijens; Wim Annaert
Journal:  J Biol Chem       Date:  2006-07-14       Impact factor: 5.157

View more
  7 in total

1.  Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates.

Authors:  Ping Gong; Kulandaivelu S Vetrivel; Phuong D Nguyen; Xavier Meckler; Haipeng Cheng; Maria Z Kounnas; Steven L Wagner; Angèle T Parent; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

2.  Mutations in nicastrin protein differentially affect amyloid beta-peptide production and Notch protein processing.

Authors:  Annelie Pamrén; Johanna Wanngren; Lars O Tjernberg; Bengt Winblad; Ratan Bhat; Jan Näslund; Helena Karlström
Journal:  J Biol Chem       Date:  2011-07-18       Impact factor: 5.157

3.  The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes.

Authors:  Mathew J Sharman; Seyyed H Moussavi Nik; Mengqi M Chen; Daniel Ong; Linda Wijaya; Simon M Laws; Kevin Taddei; Morgan Newman; Michael Lardelli; Ralph N Martins; Giuseppe Verdile
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

4.  γ-Secretase complexes containing caspase-cleaved presenilin-1 increase intracellular Aβ(42) /Aβ(40) ratio.

Authors:  Louise Hedskog; Camilla A Hansson Petersen; Annelie I Svensson; Hedvig Welander; Lars O Tjernberg; Helena Karlström; Maria Ankarcrona
Journal:  J Cell Mol Med       Date:  2011-10       Impact factor: 5.310

5.  Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression.

Authors:  Mickael Audrain; Romain Fol; Patrick Dutar; Brigitte Potier; Jean-Marie Billard; Julien Flament; Sandro Alves; Marie-Anne Burlot; Gaelle Dufayet-Chaffaud; Alexis-Pierre Bemelmans; Julien Valette; Philippe Hantraye; Nicole Déglon; Nathalie Cartier; Jérome Braudeau
Journal:  Mol Neurodegener       Date:  2016-01-12       Impact factor: 14.195

6.  Visualizing active enzyme complexes using a photoreactive inhibitor for proximity ligation--application on γ-secretase.

Authors:  Sophia Schedin-Weiss; Mitsuhiro Inoue; Yasuhiro Teranishi; Natsuko Goto Yamamoto; Helena Karlström; Bengt Winblad; Lars O Tjernberg
Journal:  PLoS One       Date:  2013-05-24       Impact factor: 3.240

7.  Changed membrane integration and catalytic site conformation are two mechanisms behind the increased Aβ42/Aβ40 ratio by presenilin 1 familial Alzheimer-linked mutations.

Authors:  Johanna Wanngren; Patricia Lara; Karin Ojemalm; Silvia Maioli; Nasim Moradi; Lu Chen; Lars O Tjernberg; Johan Lundkvist; IngMarie Nilsson; Helena Karlström
Journal:  FEBS Open Bio       Date:  2014-04-24       Impact factor: 2.693

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.